Results 101 to 110 of about 552 (131)

Identifying genetic and cellular connections and distinctions among 15 autoimmune diseases using an in-silico approach. [PDF]

Commun Med (Lond)
Dang X, Wang FQ, Zhang C, Lei Y, Su H, Yang CX, Feng H, She CH, Chen X, Yang XT, Yang J, Lau YL, Wang YF, Yang W.   +13 more
europepmc   +1 more source

The role of interleukin-6 in diabetic retinal disease: pathophysiology and therapeutic targeting. [PDF]

Front Immunol
Harlow REA, Rose-John S, Haskova Z, Fauser S, Mesquida M.   +4 more
europepmc   +1 more source

Gene Expression Alterations in Peripheral Blood Mononuclear Cells and Cartilage Explants from End-Stage Rheumatoid Arthritis Patients in Response to Taurine: A Pilot Exploratory Study. [PDF]

Life (Basel)
Tchetina E, Kushnareva I, Anisimova E, Vienozinskaite A, Plastinina O, Makarov M, Lila A.   +6 more
europepmc   +1 more source

Higher admission IL-6 levels are associated with higher platelet levels at discharge in sepsis patients. [PDF]

Ann Med Surg (Lond)
Qin M, Lu X, Walline JH, Song Z, Zhu H, Gao Y, Li Y.   +6 more
europepmc   +1 more source

STAT3 Signaling Pathway in Health and Disease. [PDF]

MedComm (2020)
Samad MA, Ahmad I, Hasan A, Alhashmi MH, Ayub A, Al-Abbasi FA, Kumer A, Tabrez S.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis

New England Journal of Medicine, 2022
The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.In a 24-week, phase 3, multicenter, placebo- and active-controlled trial, we randomly assigned (in a 2:2:2:1 ratio ...
Josef S Smolen, Eugen Feist, Saeed Fatenejad   +2 more
exaly   +3 more sources

Discovery and characterization of olokizumab [PDF]

MAbs, 2014
Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at "Site 3",
Bruce Carrington, Terry Baker
exaly   +3 more sources

Experience of olokizumab use in COVID-19 patients

Respiratory infections and bronchiectasis, 2021
Vladimir Antonov, Galina Ignatova, Semen Zotov   +2 more
exaly   +2 more sources

Efficacy of olokizumab in patients with mild or moderate COVID-19 and risk factors of progression

PULMONOLOGIYA, 2023
The COronaVIrus Disease 2019 (COVID-19) is a common infectious disease characterized by hyperactivation of the immune response and the development of a “cytokine storm” upon progression. The aim of this study was to obtain additional information about the efficacy of the drug olokizumab in comparison with the Janus kinase inhibitor upadacitinib in real
D. S. Fomina, S. S. Andreev, G. V. Andrenova, T. S. Kruglova, D. M. Demidchik, O. S. Kovalevskaya, Z. Yu. Mutovina, E. A. Dokukina, O. V. Filon, A. V. Petkova, E. K. Khanonina, M. Yu. Samsonov   +11 more
openaire   +1 more source

Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study

International Journal of Rheumatic Diseases
AbstractAimEvaluate the efficacy and safety ® (olokizumab) in patients with rheumatoid arthritis (RA) in real‐world clinical practice, with a targeted assessment of patient report outcomes (PRO) and central sensitization.MethodsAn open‐label observational non‐interventional study was conducted, enrolling 183 patients with moderate and severe RA ...
A E Karateev, E S Filatova, V N Amirdzhanova   +2 more
exaly   +3 more sources